X4 Pharmaceuticals (XFOR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.64, +7.76% vs the prior close of $2.45.
- Volume 549.80K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
XFOR jumps 7.8% to $2.64. Closed at $2.64, +7.76% vs the prior close of $2.45. Day range $2.47–$2.65, opened at $2.48.
XFOR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — XFOR jumps 7.8% to $2.64
- Closed at $2.64, +7.76% vs the prior close of $2.45. Day range $2.47–$2.65, opened at $2.48.
- Volume was 549.80K shares, 0.6x its 50-day average of 905.61K.
- Price is -26.2% vs its 50-day average ($3.58) and -31.4% vs its 200-day average ($3.85).
- 52-week range $2.43–$4.83; today's close sits at 9% of that range, 45.3% below the 52-week high.
Oct 14, 2026 — XFOR slides 5.8% to $2.45, a 52-week low, 3 down days in a row
- Closed at $2.45, -5.77% vs the prior close of $2.60. Day range $2.43–$2.55, opened at $2.54.
- Volume was 705.70K shares, 0.8x its 50-day average of 903.59K.
- Price is -32.1% vs its 50-day average ($3.61) and -36.4% vs its 200-day average ($3.85).
- 52-week range $2.43–$4.83; today's close sits at 1% of that range, 49.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — XFOR slides 7.8% to $2.60, a 52-week low
- Closed at $2.60, -7.80% vs the prior close of $2.82. Day range $2.59–$2.83, opened at $2.81.
- Volume was 439.50K shares, 0.5x its 50-day average of 902.09K — lighter than usual.
- Price is -28.6% vs its 50-day average ($3.64) and -32.7% vs its 200-day average ($3.86).
- 52-week range $2.59–$4.83; today's close sits at 0% of that range, 46.2% below the 52-week high.
Oct 12, 2026 — XFOR slides 3.1% to $2.82
- Closed at $2.82, -3.09% vs the prior close of $2.91. Day range $2.81–$2.93, opened at $2.89.
- Volume was 404.30K shares, 0.4x its 50-day average of 902.31K — lighter than usual.
- Price is -23.2% vs its 50-day average ($3.67) and -27.2% vs its 200-day average ($3.87).
- 52-week range $2.70–$4.83; today's close sits at 6% of that range, 41.6% below the 52-week high.
Oct 9, 2026 — XFOR jumps 4.3% to $2.91
- Closed at $2.91, +4.30% vs the prior close of $2.79. Day range $2.82–$2.96, opened at $2.83.
- Volume was 541.20K shares, 0.6x its 50-day average of 901.57K.
- Price is -21.3% vs its 50-day average ($3.70) and -25.0% vs its 200-day average ($3.88).
- 52-week range $2.70–$4.83; today's close sits at 10% of that range, 39.8% below the 52-week high.
Oct 8, 2026 — XFOR dips 0.7% to $2.79
- Closed at $2.79, -0.71% vs the prior close of $2.81. Day range $2.70–$2.81, opened at $2.77.
- Volume was 836.50K shares, 0.9x its 50-day average of 902.36K.
- Price is -25.0% vs its 50-day average ($3.72) and -28.2% vs its 200-day average ($3.89).
- 52-week range $2.70–$4.83; today's close sits at 4% of that range, 42.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — XFOR rises 1.4% to $2.81
- Closed at $2.81, +1.44% vs the prior close of $2.77. Day range $2.70–$2.86, opened at $2.74.
- Volume was 435.40K shares, 0.5x its 50-day average of 910.88K — lighter than usual.
- Price is -24.9% vs its 50-day average ($3.74) and -27.8% vs its 200-day average ($3.89).
- 52-week range $2.70–$4.83; today's close sits at 5% of that range, 41.8% below the 52-week high.
Oct 6, 2026 — XFOR slides 4.5% to $2.77, a 52-week low
- Closed at $2.77, -4.48% vs the prior close of $2.90. Day range $2.70–$2.90, opened at $2.90.
- Volume was 642.50K shares, 0.7x its 50-day average of 905.20K.
- Price is -26.4% vs its 50-day average ($3.76) and -28.9% vs its 200-day average ($3.89).
- 52-week range $2.70–$4.83; today's close sits at 3% of that range, 42.7% below the 52-week high.
Oct 5, 2026 — XFOR rises 2.5% to $2.90
- Closed at $2.90, +2.47% vs the prior close of $2.83. Day range $2.73–$2.93, opened at $2.88.
- Volume was 698.10K shares, 0.8x its 50-day average of 902.71K.
- Price is -23.4% vs its 50-day average ($3.79) and -25.6% vs its 200-day average ($3.90).
- 52-week range $2.73–$4.83; today's close sits at 8% of that range, 40.0% below the 52-week high.
Oct 2, 2026 — XFOR ends flat (+0.0%) to $2.83, 4 down days in a row
- Closed at $2.83, +0.00% vs the prior close of $2.83. Day range $2.74–$2.86, opened at $2.86.
- Volume was 911.40K shares, 1.0x its 50-day average of 896.08K.
- Price is -25.7% vs its 50-day average ($3.81) and -27.5% vs its 200-day average ($3.90).
- 52-week range $2.74–$4.83; today's close sits at 4% of that range, 41.4% below the 52-week high.
- That makes 4 straight losses.
XFOR latest news & SEC filings
Every SEC filing by or about XFOR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kirske David sold 11,767 shares at $2.86 (≈$33.66K) on Oct 1, 2026; now holds 155,983
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Volpone John sold 24,576 shares at $4.44 (≈$109.12K) on Aug 12, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Craig Adam R sold 47,436 shares at $4.44 (≈$210.62K) on Aug 12, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $8.81M (prior year $1.97M) (+346.3% vs Jun 30, 2025)
- Net income: -$16.16M (prior year -$25.74M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.13 (prior year -$3.47) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade XFOR
- Last results release: Nov 5, 2025 (8-K Item 2.02). Previous ones: May 1, 2025, Mar 25, 2025, Nov 13, 2024. Based on that rhythm, the next report is likely around Feb 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.20% (largest 9.3%). That is a volatile stock.
- Liquidity: about 951.38K shares (≈$2.51M) trade per day on average.
- 52-week position: $2.64 vs a range of $2.43–$4.83 (9% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:30 on Apr 28, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 4 sales; latest: Adam R Craig sold 47,436 shares on Aug 12, 2026.
- Latest filings: 8-K Oct 8, 2026; 8-K Sep 9, 2026; 8-K Sep 8, 2026.
- Share count: 99.15M shares outstanding (Jul 31, 2026), +769.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
XFOR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.48 | 2.65 | 2.47 | 2.64 | 549.80K |
| Oct 14, 2026 | 2.54 | 2.55 | 2.43 | 2.45 | 705.70K |
| Oct 13, 2026 | 2.81 | 2.83 | 2.59 | 2.60 | 439.50K |
| Oct 12, 2026 | 2.89 | 2.93 | 2.81 | 2.82 | 404.30K |
| Oct 9, 2026 | 2.83 | 2.96 | 2.82 | 2.91 | 541.20K |
| Oct 8, 2026 | 2.77 | 2.81 | 2.70 | 2.79 | 836.50K |
| Oct 7, 2026 | 2.74 | 2.86 | 2.70 | 2.81 | 435.40K |
| Oct 6, 2026 | 2.90 | 2.90 | 2.70 | 2.77 | 642.50K |
| Oct 5, 2026 | 2.88 | 2.93 | 2.73 | 2.90 | 698.10K |
| Oct 2, 2026 | 2.86 | 2.86 | 2.74 | 2.83 | 911.40K |
| Oct 1, 2026 | 2.89 | 2.95 | 2.82 | 2.83 | 501.50K |
| Sep 30, 2026 | 2.93 | 2.93 | 2.85 | 2.90 | 1.76M |
| Sep 29, 2026 | 3.01 | 3.06 | 2.89 | 2.90 | 1.71M |
| Sep 28, 2026 | 3.00 | 3.04 | 2.81 | 3.02 | 838.30K |
| Sep 25, 2026 | 2.98 | 3.08 | 2.96 | 3.01 | 1.86M |
| Sep 24, 2026 | 3.10 | 3.10 | 2.95 | 3.00 | 973.60K |
| Sep 23, 2026 | 3.41 | 3.42 | 3.04 | 3.11 | 2.31M |
| Sep 22, 2026 | 3.52 | 3.57 | 3.40 | 3.43 | 922.40K |
| Sep 21, 2026 | 3.58 | 3.58 | 3.45 | 3.49 | 444.40K |
| Sep 18, 2026 | 3.48 | 3.63 | 3.48 | 3.58 | 1.54M |
About X4 Pharmaceuticals
X4 Pharmaceuticals (XFOR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1501697.
XFOR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gary Bridger | Director | Jan 7, 2026 |
| Adam R Craig | Executive Chairman | Aug 13, 2026 |
| Kelly Gold | Director | Jul 1, 2026 |
| Murray Stewart | Director | Jan 5, 2026 |
| Michael S Wyzga | Director | Jan 5, 2026 |
| Craecker Francoise De | Director | Jan 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Adam R Craig | Executive Chairman | Aug 13, 2026 |
| David Kirske | Chief Financial Officer | Jul 1, 2026 |
| John Volpone | President | Aug 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Adam R Craig | Sale | 47,436 | $4.44 |
| Aug 12, 2026 | John Volpone | Sale | 24,576 | $4.44 |
| Jun 30, 2026 | David Kirske | Sale | 8,543 | $4.26 |
| May 12, 2026 | David Kirske | Sale | 16,961 | $4.29 |
| Oct 23, 2025 | Adam R Craig | Buy | 86,206 | $2.90 |
XFOR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $35.11M | $-79.20M | -1.87 | $-85.62M |
| Dec 31, 2024 | $2.56M | $-37.45M | -5.59 | $-130.90M |
| Dec 31, 2023 | $0 | $-101.17M | -17.07 | $-96.51M |
| Dec 31, 2022 | $0 | $-93.87M | -1.52 | $-77.10M |
| Dec 31, 2021 | $0 | $-88.70M | -3.99 | $-70.91M |
Latest balance sheet: total assets $253.06M, total liabilities $97.61M, cash $195.09M (as of Jun 30, 2026).
XFOR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Nov 5, 2025 | 8-K Item 2.02 (results) | $3.55 |
| May 1, 2025 | 8-K Item 2.02 (results) | $3.75 |
| Mar 25, 2025 | 8-K Item 2.02 (results) | $7.77 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $8.31 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
| May 4, 2023 | 8-K Item 2.02 (results) | — |
| Mar 21, 2023 | 8-K Item 2.02 (results) | — |
| Nov 3, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on XFOR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.